Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has provided an announcement.
On May 5, 2026, Eupraxia Pharmaceuticals reported new Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from the Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis, presented at the Digestive Disease Week conference in Chicago. The data showed that patients receiving a full protocol of 20 esophageal wall injections had greater and more consistent improvements in both inflammatory and fibrotic EREFS subscores than those given fewer injections, supporting the 20-injection regimen now being used in the ongoing placebo-controlled Phase 2b portion of RESOLVE and reinforcing EP-104GI’s potential as a targeted local therapy in a rapidly growing EoE market.
Among 30 participants, 83% started with EREFS scores above 2, and in those with higher baseline scores, the proportion achieving response thresholds of 2 or less at week 12 rose with the number of injections. In the subgroup of seven patients who received 20 injections, mean EREFS fell by 65% from baseline and near-complete improvement was seen in the highest-dose cohorts, underscoring a dose-coverage relationship that may strengthen Eupraxia’s positioning as it recruits for the Phase 2b trial and prepares to deliver top-line data expected in the fourth quarter of 2026.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on EPRX Stock
According to Spark, TipRanks’ AI Analyst, EPRX is a Neutral.
The score is held back primarily by the pre-revenue model with widening losses and rising cash burn, despite a notably improved, low-debt balance sheet. Technical indicators also reflect weak near-term momentum, and valuation signals are limited by negative earnings and lack of dividend support.
To see Spark’s full report on EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing locally delivered, extended-release therapies using its proprietary Diffusphere technology to optimize controlled drug delivery. The company is focused on areas of high unmet medical need, currently advancing treatments for inflammatory gastrointestinal diseases and pain, with potential applications in oncology, infectious disease and other indications.
Average Trading Volume: 75,014
Technical Sentiment Signal: Buy
Current Market Cap: C$625.6M
Learn more about EPRX stock on TipRanks’ Stock Analysis page.